SUMMARY

• No data evaluating the use of UPTRAVI with coronavirus disease 2019 (COVID-19) have been published.
• For patients currently taking UPTRAVI who have been diagnosed with COVID-19, clinicians should use clinical judgment to decide whether to delay treatment until the patient is recovered or continue treatment as scheduled. It will be important to evaluate the risk-benefit of continued treatment based on the patient’s clinical status in terms of pulmonary arterial hypertension (PAH) symptoms versus the severity of symptoms from COVID-19.
• If a decision is made to continue treatment, appropriate precautions should be taken to minimize the potential for spreading the infection and protecting the clinical staff.

ADDITIONAL INFORMATION and RESOURCES

Please note, this is not a complete list of publicly available resources available pertaining to this topic.

Publicly Available Websites: United States (US) Government and World Health Organization (WHO)

• For information from the US Centers for Disease Control and Prevention (CDC), visit: COVID-19.
• For information from the US Food and Drug Administration (FDA), visit: Coronavirus Disease 2019 (COVID-19).
• For information from the WHO, visit: Coronavirus disease (COVID-19) pandemic.

Publicly Available Websites: Patient-Related Foundations within the Janssen Pulmonary Hypertension Therapeutic Area

• American Lung Association (ALA): Protecting Yourself and Loved Ones During the Coronavirus Disease (COVID-19) Pandemic.
• Pulmonary Hypertension Association (PHA): COVID-19 and Pulmonary Hypertension.

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, DERWENT^® (and/or other resources, including internal databases) was conducted on 11 September 2024.